Magenta Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th, 2018
CAMBRIDGE, Mass. – January 5th, 2018 – Magenta Therapeutics, a biotechnology company developing therapeutics to improve and extend the use of curative bone marrow transplant for more patients, today announced that Jason Gardner, D.Phil., CEO, president and co-founder of Magenta, will provide a company presentation at the 36th Annual J.P. Morgan Healthcare Conference.
The presentation will take place on Tuesday, January 9th, 2018 at 3:30 p.m. PT at the Westin St. Francis in San Francisco, Calif.
About Bone Marrow Transplant
Healthy bone marrow stem cells and the blood cells they create are crucial for survival, but certain diseases can affect the bone marrow, interfering with its ability to function properly. A bone marrow transplant is a process to replace unhealthy bone marrow with healthy bone marrow stem cells. Bone marrow transplant can save the lives of patients with blood cancers and genetic diseases and is a potential cure for patients with severe refractory autoimmune diseases. However, the high risks, toxic side effects and complexity of the procedure currently prevent many patients from being able to benefit.
About Magenta Therapeutics
Magenta Therapeutics is a biotechnology company developing therapeutics to revolutionize bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of unmet need, Magenta Therapeutics is pioneering an integrated approach to extend the curative power of bone marrow transplant to more patients. Founded by internationally recognized leaders in bone marrow transplant medicine, Magenta Therapeutics was launched in 2016 by Third Rock Ventures and Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit www.magentatx.com.
Manisha Pai, Vice President, Communications & Investor Relations